Background/Aims Impaired esophageal motility and disrupted esophagogastric junction (EGJ) on high-resolution manometry (HRM) have been associated with increased reflux severity in gastroesophageal reflux disease (GERD) patients. However, there are limited data evaluating HRM parameters in proton pump inhibitors (PPI) non-responders. Methods Clinical and endoscopic data, HRM and multichannel intraluminal impedance-pH studies performed of PPI therapy in patients with typical GERD symptoms were reviewed from 3 international centers. Frequency of GERD symptoms was assessed on and off PPI therapy in both non-responders (< 50% symptom improvement on PPI therapy) and responders. Rome IV definitions identified non-erosive reflux disease, reflux hyp...
Available data about reflux patterns and symptom determinants in the gastroesophageal reflux disease...
BACKGROUND: On-therapy impedance-pH monitoring in proton pump inhibitor (PPI)-refractory gastroesoph...
Background. The number of patients with proton pump inhibitor (PPI)-refractory reflux symptoms is un...
Background/Aims: Impaired esophageal motility and disrupted esophagogastric junction (EGJ) on high-r...
Background/Aims The role of esophageal high-resolution manometry (HRM) within Lyon consensus phenoty...
Background: The real size of the gastro-oesophageal reflux disease (GERD) population not responding ...
Gastroesophageal reflux disease (GERD) is a condition, which develops when the reflux of stomach con...
BACKGROUND AND AIM: Few data describing short-term proton pump inhibitor (PPI) treatment in patient...
BACKGROUND Etiology of gastro-esophageal reflux disease (GERD) is multifactorial, but incompetence o...
Background Inadequate response to proton pump inhibitor (PPI) therapy in patients with gastroesophag...
Background: The Lyon Consensus delineates impedance-pH parameters that can demonstrate/exclude gastr...
BACKGROUND: A short-course of proton pump inhibitors (PPIs) is often used to confirm gastroesophagea...
Proton pump inhibitor (PPI) therapy is the mainstay of treatment for gastroesophageal reflux disease...
Aim. The aim of the study is to analyze the regularities of changes in the basic indicators of esop...
Objective: Heartburn is the most specific symptom of reflux disease and is highly responsive to prot...
Available data about reflux patterns and symptom determinants in the gastroesophageal reflux disease...
BACKGROUND: On-therapy impedance-pH monitoring in proton pump inhibitor (PPI)-refractory gastroesoph...
Background. The number of patients with proton pump inhibitor (PPI)-refractory reflux symptoms is un...
Background/Aims: Impaired esophageal motility and disrupted esophagogastric junction (EGJ) on high-r...
Background/Aims The role of esophageal high-resolution manometry (HRM) within Lyon consensus phenoty...
Background: The real size of the gastro-oesophageal reflux disease (GERD) population not responding ...
Gastroesophageal reflux disease (GERD) is a condition, which develops when the reflux of stomach con...
BACKGROUND AND AIM: Few data describing short-term proton pump inhibitor (PPI) treatment in patient...
BACKGROUND Etiology of gastro-esophageal reflux disease (GERD) is multifactorial, but incompetence o...
Background Inadequate response to proton pump inhibitor (PPI) therapy in patients with gastroesophag...
Background: The Lyon Consensus delineates impedance-pH parameters that can demonstrate/exclude gastr...
BACKGROUND: A short-course of proton pump inhibitors (PPIs) is often used to confirm gastroesophagea...
Proton pump inhibitor (PPI) therapy is the mainstay of treatment for gastroesophageal reflux disease...
Aim. The aim of the study is to analyze the regularities of changes in the basic indicators of esop...
Objective: Heartburn is the most specific symptom of reflux disease and is highly responsive to prot...
Available data about reflux patterns and symptom determinants in the gastroesophageal reflux disease...
BACKGROUND: On-therapy impedance-pH monitoring in proton pump inhibitor (PPI)-refractory gastroesoph...
Background. The number of patients with proton pump inhibitor (PPI)-refractory reflux symptoms is un...